Table 2. Disclosures.
| # | Name | C T A | Conflict | # | Brief Description | >or<10K |
|---|---|---|---|---|---|---|
| 1 | Emelia J Benjamin | Y | 1. Research Grant | 3 |
HL076784 and AG028321
Identification of Common Genetic Variants for AF & PR Interval 1RO1HLO92577-01A1 Benjamin & Ellinor (Pending) |
>10K |
| 2 | Peng-Sheng Chen | Y | 1. Research Grants | R01 HL71140, R01 HL78932, P50 HL78931 | >10K | |
| Y | 2. Other Research Support | 1 | Medtronic & CryoCath donated equipment to my laboratory | >10K | ||
| 7. Consultant/Advisory Board | 1 | I am a consultant to Medtronic Inc. | <10K | |||
| 3 | Diane E Bild | Y | None | 0 | NIH, NHLBI employee | |
| 4 | Alice Mascette | Y | Consultant/Advisory Board | PRECISION tied Exec Board (Pfizer) UNPAID Member | $0 | |
| 5 | Christine M. Albert | Y | None | 0 | ||
| 6 | Alvaro Alonso | Y | 1. Research Grant | 1 | Co-investigator to contract funded by NIH (ARIC and MESA) | >10K |
| 7 | Hugh Calkins | Y | 1. Research Grants | 3 | BioSense Webster – study | >10K |
| CryoCath – clinical trial | >10K | |||||
| ProRhythm – clinical trial | >10K | |||||
| 4. Honoraria | 3 | BioSense Webster | <10K | |||
| Medtronic | <10K | |||||
| Sanofi-Aventis | <10K | |||||
| 7. Consultant/Advisory Board | 5 | CryoCath | <10K | |||
| Ablation Frontiers | <10K | |||||
| ProRhythm | <10K | |||||
| Sanofi-Aventis | <10K | |||||
| BioSense Webster | <10K | |||||
| Medtronic | <10K | |||||
| 8 | Stuart J Connolly | ? | 1. Research Grants | 2 | Sanofi-Aventis | >10K |
| BMS | >10K | |||||
| 9 | Anne B Curtis | Y | 1. Research Grant | 1 | CV Therapeutics | <10K |
| 7. Consultant/Advisory Board | 2 | Sanofi-Aventis | <10K | |||
| 10 | Dawood Darbar | Y | 1. Research Grant | 2 | Genetic Basis of AF5K23HLO75266 | >10K |
| QT remodeling in AF 1 RO1 HL085690 | >10K | |||||
| 11 | Patrick T Ellinor | Y | 1. Research Grant | 2 | The Genetic Basis of AF 5 RO1HLO75431 MacRae | >10K |
| Identification of Common Genetic Variants for AF & PR Interval
1RO1HLO92577-01A1 Benjamin & Ellinor (Pending) |
>10K | |||||
| 3. Speaker's Bureau | 1 | Sanofi-Aventis | <10K | |||
| 12 | Alan Go | Y | 1. Research Grant | 1 | Research Grant from Johnson & Johnson | >10K |
| 13 | Nora Goldschlager | Y | 4. Honoraria | 1 | St Jude Medical | <10K |
| 5. Expert Witness | 1 | <10K | ||||
| 14 | Susan R. Heckbert | Y | 1. Research Grant | 1 | NHLBI Grant 068986 “Atrial Fibrillation incidence, risk factors & genetics | >10K |
| 15 | Jose Jalife | Y | 1. Research Grant | 3 | RO1HL039707 | >10K |
| RO1HL087226 | >10K | |||||
| RO1HL070074 | >10K | |||||
| 4. Honoraria | 2 | Boston AF Symposium | <10K | |||
| Johnson & Johnson | <10K | |||||
| 16 | Charles R. Kerr | Y | 1. Research Grant | 2 | St. Jude Medical, Canada | >10K |
| Sanofi-Aventis, Canada “Canadian Registry of Atrial Fibrillation” | >10K | |||||
| Consultant/Advisory Board | 1 | Sanofi-Aventis, Canada | <10K | |||
| 17 | Daniel Levy | Y | None | 0 | ||
| 18 | Don Lloyd-Jones | Y | None | 0 | ||
| 19 | Barry M Massie | 1. Research Grants | 3 | VA HSR&D: Optimal use & cost-effectiveness of ICDs in the VA Health Care System
Bristol Myers Squibb Sanofi Aventis |
∼$1,200,000 over 5 years
∼$100,000 over 6 years ∼$120,000 over 4 years |
|
| Y | 4. Speaking Honoraria | 1 | Heart Failure Society of America (CME Program)
Merck |
<10K
<10K |
||
| 7. Consulting | 6 | Sanofi-Aventis
Merck GlaxoSmithKline Novartis Duke Clinical Research Institute Bristol-Myers Squibb |
<10K
<10K <10K <10K >10K >10K |
|||
| DSMB Payments | 4 | Takeda
Scios J&J Corthera Medtronic (just beginning, no payments but expect to be <$10,000) |
<10K
<10K <10K <10K |
|||
| 20 | Stanley Nattel | Y | Institution/Employer | 2 | I am listed as investigator on Montreal Heart Institute Intellectual Property for Statin drugs to treat AF | <10K |
| Pierre Fabre Company (France) Study of Fish oil derivative, AF model | >10K | |||||
| 21 | Jeffrey E Olgin | Y | 1. Research grant | 1 | InterMune Inc. Grant to study effects of an anti fibrotic on AF | >10K |
| 22 | Douglas Packer | Y | 1. Research grant | 6 | Boston Scientific/EPT | >10K |
| St Jude Medical/St Jude Foundation | >10K | |||||
| CryoCath Technologies | >10K | |||||
| ProRhythm | >10K | |||||
| Cardio Focus | >10K | |||||
| BioSense Webster Inc. | >10K | |||||
| 4. Honoraria | 3 | BioSense Webster Inc. | <10K | |||
| St Jude Medical | <10K | |||||
| CryoCath Technologies | <10K | |||||
| 6. Ownership Interests | 1 | I receive royalties from St. Medical/EST for licensed intellectual property | ||||
| 7. Consultant Advisory Board | 6 | Boston Scientific/EPT | <10K | |||
| St Jude Medical/St Jude Foundation | <10K | |||||
| CryoCath Technologies | <10K | |||||
| ProRhythm | <10K | |||||
| Cardio Focus | <10K | |||||
| BioSense Webster Inc. | <10K | |||||
| 23 | Sunny Po | Y | 1. Research Grant | 1 | Nanoparticles as a Lone Delivery System (PI) | >10K |
| 4. Honoraria | 1 | AtriCure | <10K | |||
| 24 | Teresa S M Tsang | Y | 1. Research Grant | 3 | NIH NIA Pathophysiology of AF | >10K |
| American Society of Echocardiography – LA remodeling | >10K | |||||
| CR20 Mayo Foundation | >10K | |||||
| 25 | David R Van Wagner | Y | 1. Research Grant | 3 | Atrial Fibrillation Innovation Center, Ohio Wright Center Initiative | >10K |
| Fondation Leducq Atrial Fibrillation Research Consortium | >10K | |||||
| NIH RO1 Genetics of Atrial Fibrillation | >10K | |||||
| 26 | Albert L Waldo | Y | 1. Research Grant: | 3 | Boehringer Ingelheim RELY trial | >10K |
| Bristol-Myers Squibb – (Aristotle trial), anticipated has not yet started | >10K | |||||
| CARDAX Pharmaceuticals | >10K | |||||
| 2. Other Research Support | 1 | Wright Third Frontier Grant From The State of Ohio | >10K | |||
| 4. Honorarium | 4 | Grand Rounds, Vanderbilt | <10K | |||
| NIH/NHLBI-CCRN DSMB | <10K | |||||
| NEOSPE SYMPOSIUM | <10K | |||||
| Boston AF Symposium | <10K | |||||
| 7. Consultant/Advisory Board | 2 | Astellas
Biotronik St Jude Medical AstraZeneca |
<10K | |||
| Deugen; SCIOS; Bristol-Myers Squibb | <10K | |||||
| BioSense Webster; Solvay; CryoCor; Sanofi Aventis | >10K | |||||
| 27 | D. George Wyse | Y | 4. Honorarium | 1 | Talk on advisory board at Astellas | <10K |
| 7. Consultant/Advisory Board | 9 | (a) Boehringer Ingelheim – DSMB Member | <10K | |||
| (b) Novartis Advisory Board to plan RCT | <10K | |||||
| (c) Cardiome / Astellas – Advisory Board concerning new product | <10K | |||||
| (d) Medtronic – Advisory Board to plan RCT; DSMB; Advisory Board for Registry Study | <10K | |||||
| (e) Sanofi-Aventis – Chair DSMB | <10K | |||||
| (f) CV Therapeutics – Advisory Board to plan RCT | <10K | |||||
| (g) Transoma – Advisory Board to plan RCT | <10K | |||||
| (h) Bristol Myers Squib – DSMB Member | <10K | |||||
| (i) Biotronik – Chair DSMB | <10K |